Revisiting Telomere Shortening in Cancer
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Telomeres, the protective structures of chromosome ends are gradually shortened by each cell division, eventually leading to senescence or apoptosis. Cancer cells maintain the telomere length for unlimited growth by telomerase reactivation or a recombination-based mechanism. Recent genome-wide analyses have unveiled genetic and epigenetic alterations of the telomere maintenance machinery in cancer. While telomerase inhibition reveals that longer telomeres are more advantageous for cell survival, cancer cells often have paradoxically shorter telomeres compared with those found in the normal tissues. In this review, we summarize the latest knowledge about telomere length alterations in cancer and revisit its rationality. Finally, we discuss the potential utility of telomere length as a prognostic biomarker.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575 · cited 1×
“One of the glioblastoma subtypes, proneural subtype, has features of high expression of platelet derived growth factor receptor alpha (PDGFRA) or isocitrate dehydrogenase 1 (IDH1) gene mutation [138].”
BackgroundShelterin: the protein complex that shapes and safeguards human telomeres
de Lange, T. (2005) · Genes & Development · doi:10.1101/gad.1346005 · Cited by 3,056 · cited 6×
“POT1 limits telomerase access to G-overhangs by binding to single-stranded DNA [36], whereas TPP1 interacts with telomerase to promote telomerase processivity [4,5,37].”
BackgroundInfluentialA survey of telomerase activity in human cancer
Shay, J. W., & Bacchetti, S. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)00062-2 · Cited by 2,794 · cited 1×
“Of all cancer cells, 85–95% expresses telomerase, whereas ~5–15% exhibit ALT pathway activation [1,2].”
BackgroundDriver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
Schwartzentruber, J., Korshunov, A., Liu, X.-Y., Jones, D. T. W., Pfaff, E., Jacob, K., Sturm, D., Fontebasso, A. M., Quang, D.-A. K., Tönjes, M., et al. (2012) · Nature · doi:10.1038/nature10833 · Cited by 2,631
Mammalian Telomeres End in a Large Duplex Loop
Griffith, J. D., Comeau, L., Rosenfield, S., Stansel, R. M., Bianchi, A., Moss, H., & de Lange, T. (1999) · Cell · doi:10.1016/s0092-8674(00)80760-6 · Cited by 2,447
Telomerase Catalytic Subunit Homologs from Fission Yeast and Human
Nakamura, T. M., Morin, G. B., Chapman, K. B., Weinrich, S. L., Andrews, W. H., Lingner, J., Harley, C. B., & Cech, T. R. (1997) · Science · doi:10.1126/science.277.5328.955 · Cited by 2,256 · cited 2×
“In addition, most cancer cells acquire telomerase activity by re-expressing the limiting factor TERT [7,8].”
BackgroundThe RNA Component of Human Telomerase
Feng, J., Funk, W. D., Wang, S.-S., Weinrich, S. L., Avilion, A. A., Chiu, C.-P., Adams, R. R., Chang, E., Allsopp, R. C., Yu, J., et al. (1995) · Science · doi:10.1126/science.7544491 · Cited by 2,227 · cited 1×
“In human normal somatic cells, TERC is constitutively expressed, whereas TERT expression is epigenetically silenced [6,7].”
BackgroundTERT Promoter Mutations in Familial and Sporadic Melanoma
Horn, S., Figl, A., Rachakonda, P. S., Fischer, C., Sucker, A., Gast, A., Kadel, S., Moll, I., Nagore, E., Hemminki, K., et al. (2013) · Science · doi:10.1126/science.1230062 · Cited by 1,799 · cited 3×
“Horn’s group and Huang’s group discovered point mutation in the promoter at −124 (C > T) and −146 base pairs (C > T) from the transcription start site (TSS) (also termed C228T and C250T as these positions are at chromosome 5, 1,295,228 C > T and 1,295,250 C > T, respectively) in sporadic melanoma [40,41].”
BackgroundMeyerson, M., Counter, C. M., Eaton, E. N., Ellisen, L. W., Steiner, P., Caddle, S. D., Ziaugra, L., Beijersbergen, R. L., Davidoff, M. J., Liu, Q., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80538-3 · Cited by 1,784
Killela, P. J., Reitman, Z. J., Jiao, Y., Bettegowda, C., Agrawal, N., Diaz, L. A., Friedman, A. H., Friedman, H., Gallia, G. L., Giovanella, B. C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303607110 · Cited by 1,368
Hemann, M. T., Strong, M. A., Hao, L.-Y., & Greider, C. W. (2001) · Cell · doi:10.1016/s0092-8674(01)00504-9 · Cited by 1,219
Altered Telomeres in Tumors with ATRX and DAXX Mutations
Heaphy, C. M., de Wilde, R. F., Jiao, Y., Klein, A. P., Edil, B. H., Shi, C., Bettegowda, C., Rodriguez, F. J., Eberhart, C. G., Hebbar, S., et al. (2011) · Science · doi:10.1126/science.1207313 · Cited by 1,083
Mammalian Telomeres Resemble Fragile Sites and Require TRF1 for Efficient Replication
Sfeir, A., Kosiyatrakul, S. T., Hockemeyer, D., MacRae, S. L., Karlseder, J., Schildkraut, C. L., & de Lange, T. (2009) · Cell · doi:10.1016/j.cell.2009.06.021 · Cited by 990
Chin, L., Artandi, S. E., Shen, Q., Tam, A., Lee, S.-L., Gottlieb, G. J., Greider, C. W., & DePinho, R. A. (1999) · Cell · doi:10.1016/s0092-8674(00)80762-x · Cited by 979 · cited 2×
“However, some cells that can overcome senescence by the acquisition of genetic mutations in p53 or other checkpoint proteins continue to proliferate; thus, telomeres become critically short, and apoptosis is subsequently induced (crisis) [79,80].”
Frequency of TERT promoter mutations in human cancers
Vinagre, J., Almeida, A., Pópulo, H., Batista, R., Lyra, J., Pinto, V., Coelho, R., Celestino, R., Prazeres, H., Lima, L., et al. (2013) · Nature Communications · doi:10.1038/ncomms3185 · Cited by 898
Protection of telomeres through independent control of ATM and ATR by TRF2 and POT1
Denchi, E. L., & de Lange, T. (2007) · Nature · doi:10.1038/nature06065 · Cited by 880
The POT1-TPP1 telomere complex is a telomerase processivity factor.
Wang, F., Podell, E. R., Zaug, A. J., Yang, Y., Baciu, P., Cech, T. R., & Lei, M. (2007) · Nature · doi:10.1038/nature05454 · Cited by 704
Systematic analysis of telomere length and somatic alterations in 31 cancer types
Barthel, F. P., Wei, W., Tang, M., Martinez-Ledesma, E., Hu, X., Amin, S. B., Akdemir, K. C., Seth, S., Song, X., Wang, Q., et al. (2017) · Nature Genetics · doi:10.1038/ng.3781 · Cited by 614 · cited 4×
“examined telomere length of 18,430 samples across 31 types of cancer cohorts using whole genome sequencing or whole exome sequencing data from The Cancer Genome Atlas (TCGA) [66].”
BackgroundMethodInfluentialThe transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer
Bell, R. J. A., Rube, H. T., Kreig, A., Mancini, A., Fouse, S. D., Nagarajan, R. P., Choi, S., Hong, C., He, D., Pekmezci, M., et al. (2015) · Science · doi:10.1126/science.aab0015 · Cited by 566 · cited 1×
“In ETS family proteins, ETS1 and GA-binding protein transcription factor α (GABPA) and β1 (GABPB1) dimers are specifically recruited to the de novo ETS binding motifs in the TERT promoter, which increases telomerase enzymatic activity and telomere elongation and is correlated with poor prognosis in urothelial cancer […”
BackgroundPaediatric and adult glioblastoma: multiform (epi)genomic culprits emerge
Sturm, D., Bender, S., Jones, D. T. W., Lichter, P., Grill, J., Becher, O., Hawkins, C., Majewski, J., Jones, C., Costello, J. F., et al. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3655 · Cited by 555
A Protein-Counting Mechanism for Telomere Length Regulation in Yeast
Marcand, S., Gilson, E., & Shore, D. (1997) · Science · doi:10.1126/science.275.5302.986 · Cited by 524 · cited 1×
“As a well-established mechanism for limited telomere elongation, telomere-bound shelterin complexes exert a negative feedback effect on telomerase access to telomeres (so-called “protein-counting” mechanism) [115,116].”
BackgroundHeaphy, C. M., Subhawong, A. P., Hong, S.-M., Goggins, M. G., Montgomery, E. A., Gabrielson, E., Netto, G. J., Epstein, J. I., Lotan, T. L., Westra, W. H., et al. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.06.018 · Cited by 516
Super-Resolution Fluorescence Imaging of Telomeres Reveals TRF2-Dependent T-loop Formation
Doksani, Y., Wu, J. Y., de Lange, T., & Zhuang, X. (2013) · Cell · doi:10.1016/j.cell.2013.09.048 · Cited by 493
Ye, J. Z.-S., Hockemeyer, D., Krutchinsky, A. N., Loayza, D., Hooper, S. M., Chait, B. T., & de Lange, T. (2004) · Genes & Development · doi:10.1101/gad.1215404 · Cited by 459
PTOP interacts with POT1 and regulates its localization to telomeres
Liu, D., Safari, A., O'Connor, M. S., Chan, D. W., Laegeler, A., Qin, J., & Songyang, Z. (2004) · Nature Cell Biology · doi:10.1038/ncb1142 · Cited by 450
Wu, L., Multani, A. S., He, H., Cosme-Blanco, W., Deng, Y., Deng, J. M., Bachilo, O., Pathak, S., Tahara, H., Bailey, S. M., et al. (2006) · Cell · doi:10.1016/j.cell.2006.05.037 · Cited by 422
TRF1 is a dimer and bends telomeric DNA
Bianchi, A., Smith, S., Chong, L., Elias, P., & de Lange, T. (1997) · The EMBO Journal · doi:10.1093/emboj/16.7.1785 · Cited by 358
Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers
Kyo, S., Takakura, M., Fujiwara, T., & Inoue, M. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00878.x · Cited by 347
TERT promoter mutations and telomerase reactivation in urothelial cancer
Borah, S., Xi, L., Zaug, A. J., Powell, N. M., Dancik, G. M., Cohen, S. B., Costello, J. C., Theodorescu, D., & Cech, T. R. (2015) · Science · doi:10.1126/science.1260200 · Cited by 292
Samper, E., Flores, J. M., & Blasco, M. A. (2001) · The EMBO Reports · doi:10.1093/embo-reports/kve174 · Cited by 263
Zinn, R. L., Pruitt, K., Eguchi, S., Baylin, S. B., & Herman, J. G. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3396 · Cited by 210
Cited by
Skou, S. T., Mair, F. S., Fortin, M., Guthrie, B., Nunes, B. P., Miranda, J. J., Boyd, C. M., Pati, S., Mtenga, S., & Smith, S. M. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00376-4 · Cited by 1,362
Vaiserman, A., & Krasnienkov, D. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2020.630186 · Cited by 454
“In fact, however, cancerous cells frequently have paradoxically shorter telomeres relative to those observed in normal tissues (Okamoto and Seimiya, 2019).”
BackgroundNutrition and longevity—From mechanisms to uncertainties
Ekmekcioglu, C. (2020) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2019.1676698 · Cited by 87
Cell Immortalization: In Vivo Molecular Bases and In Vitro Techniques for Obtention
de Bardet, J. C., Cardentey, C. R., González, B. L., Patrone, D., Mulet, I. L., Siniscalco, D., & Robinson-Agramonte, M. D. L. A. (2023) · BioTech · doi:10.3390/biotech12010014 · Cited by 35
Correlation of telomere length between full and preterm neonates and their mothers
Vakonaki, E., Vitiadou, M., Paraskevopoulou, N., Tzatzarakis, M., Baliou, S., Ioannou, P., Alegakis, A., Lamprakis, T., Fragkiadaki, P., Mylonaki, E., et al. (2025) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2025.12937 · Cited by 3
Metadata
- Authors
- Okamoto, K., & Seimiya, H.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2019-01-31
- Volume
- 8
- Issue
- 2
- Pages
- 107
- ISSN
- 2073-4409 (ISSN-L)
- OpenAlex
- W2913259928
- Cited by
- 152
- References
- 31
- FWCI
- 11.57
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.